Skip to search formSkip to main contentSkip to account menu

Goserelin 10.8 MG Drug Implant [Zoladex]

Known as: GOSERELIN ACETATE 10.8 mg SUBCUTANEOUS IMPLANT [ZOLADEX], Zoladex 10.8 MG Drug Implant, Zoladex 10.8 MG Subcutaneous Drug Implant 
National Institutes of Health

Related topics

Related topics

7 relations
DL-Lactic AcidDrug ImplantGoserelinGoserelin Acetate

Broader (1)

Goserelin Drug Implant [Zoladex]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
High-risk prostate cancer is prevalent among low-income men
Risk factors for cardiovascular disease, including impaired insulin sensitivity, increased fat mass and high levels of… 
2009
2009
Adjuvant GnRH agonists do not increase cardiovascular mortality
Risk factors for cardiovascular disease, including impaired insulin sensitivity, increased fat mass and high levels of… 
2009
2009
Gastric bypass surgery improves sexual function in morbidly obese men
Risk factors for cardiovascular disease, including impaired insulin sensitivity, increased fat mass and high levels of… 
1995
1995
乳癌患者における Zoladex の副作用に対する桂枝茯苓丸の使用経験2症例
1991
1991
Hormonelle Folgetherapien nach Goserelin (Zoladex®) beim metastasierten Mammakarzinom prämenopausaler Patientinnen
Der GnRH-Agonist Zoladex® (Z) (3,6 mg Goserelin; slow releasing depot-Praparat, s.c. alle 4 Wochen appliziert) hat sich als… 
1990
1990
Goserelinazetat (Zoladex®) gegen Goserelinazetat plus Flutamid (Fugerel®) beim fortgeschrittenen Prostatakarzinom: Zwischenbericht einer Phase III-Studie
In einer offenen, randomisierten Multizenterstudie (Phase III) wurden die klinische Wirksamkeit und Vertraglichkeit der Goserelin… 
1987
1987
(ZOLADEX®) IN PATIENTS WITH PROSTATIC CARCINOMA